MarginsXMarginsX
Home › Markets › Health Care › DYAI

Dyadic International Inc. (DYAI)

DYAI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3200
-2.14% on the day
Market cap
$12.8M
Nano cap
Revenue · 2025
$3.1M
-11.6% on 2024
Net income · 2025
-$7.4M
-238.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/0001493152-26-012672-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDYAI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001213809
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.1M
Net income-$7.4M
Operating income-$7.2M
Net margin-238.3%
Operating margin-232.8%
Revenue growth-11.6%
Cash$4.6M
Total assets$9.9M
P/E (computed)Net income was not positive
P/S (computed)4.2×

Warning signs

Cash runway
2.3 months
$1.4M cash at June 30, 2026
Share count, 1 year
+10.8%
2025-11-11 to 2026-11-12 · +39.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$125K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors include, but are not limited to (i) our history of net losses, and management's related conclusion that there is substantial doubt about our ability to continue as a going concern for 12 months following November 13, 2026, the date the financial statements are issued;"
10-Q 2026-11-13
Cash and burn$1.4M cash; operating cash flow -$1.9M a quarter.Report 2026-06-30
Shares outstanding40,091,203 (2026-11-12); 36,187,798 a year earlier; 28,811,061 three years earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-13
Exchange deficiency notices, 12 months4 (8-K item 3.01)8-K 2026-09-25
AuditorCrowe LLP, Livingston, New Jersey, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $125K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$961K-$2.1M-$1.8M$1.4MNo debt tags$3.8M10-Q 2026-08-12
Q1 2026
2026-03-31
$1.1M-$2.0M-$2.0M$4.2MNo debt tags$3.8M10-Q 2026-05-13
Q4 2025
2025-12-31
$566K-$1.6M-$1.8M$4.6MNo debt tags$3.1M10-K 2026-03-25
Q3 2025
2025-09-30
$1.2M-$2.0M-$1.9M$5.8MNo debt tags$3.3M10-Q 2025-11-12
Q2 2025
2025-06-30
$967K-$1.8M-$130K$2.1MNo debt tags$4.1M10-Q 2026-08-12
Q1 2025
2025-03-31
$394K-$2.0M-$1.9M$5.1MNo debt tags$3.6M10-Q 2026-05-13
Q4 2024
2024-12-31
$817K-$1.6M-$696K$6.5MNo debt tags$3.5M10-K 2026-03-25
Q3 2024
2024-09-30
$2.0M-$203K-$201K$5.9MNo debt tags$3.4M10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-18
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-06-18

Source: SEC EDGAR submissions feed, 542 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.9%
1 month-23.3%
3 months-57.1%
Year to date-64.9%
1 year-63.7%
From 52-week high-77.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
PLURPluri Inc.$1.04-0.95%$15.0M
SCLXScilex Holding Company$1.25-12.59%$10.6M
ABOSAcumen Pharmaceuticals Inc.$0.2160+0.93%$15.6M
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier